GP-Act III Acquisition
GPATNASDAQUSD
- — Source valuation snapshot. Not a live recalculation.
- — Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- — Diluted earnings per share from the latest filed annual.
- $11.07 Prior regular-session close from the quote source.
- $11.01–$11.01 Regular-session low and high so far today.
- 895 Regular-session shares traded · Nov 11, 9:30 AM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $10.65–$12.00 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own GPAT if GP-Act III is a blank-check vehicle whose value will come only from completing a high-quality business combination that converts its ~ $300M of trust assets into an attractive public company with limited shareholder redemptions.
GPAT price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
The SPAC’s ~ $300M in assets constitutes the primary deal capital and is sufficient to underwrite a substantial business combination if the sponsor finds a suitable target.HoldingMateriality: High
assets = 297,473,660 USD (2024-12-31) -> 309,368,322 USD (2025-12-31): a large, stable asset base consistent with a SPAC trust. If the trust assets fund a meaningful merger, public shareholders can realize upside from a successful business combination; if the trust is eroded or insufficient, the SPAC must rely on dilutive sponsor/PIPE funding or liquidate.
Watch: Large shareholder redemptions on merger announcement that reduce the trust proceeds available for the target.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
assets = 297,473,660 USD (2024-12-31) -> 309,368,322 USD (2025-12-31): a large, stable asset base consistent with a SPAC trust.
Open source ↗Reported positive net income is primarily non-operating — driven by interest/mark-to-market on trust assets — and therefore does not signal an operating business or recurring operating profitability.StrengtheningMateriality: High
net_income = 8,671,665 USD (2024) -> 11,891,655 USD (2025) while operating_income remained negative: operating_income = -564,973 USD (2024) and -551,918 USD (2025). Net income today does not imply an ongoing profitable company; holders must judge the future operating economics of any merger partner, not the current GAAP net income of the SPAC.
Watch: The company announces and closes a business combination with an operating company whose operating_income becomes positive and material (i.e., the merged entity reports meaningful operating profits).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
net_income = 8,671,665 USD (2024) -> 11,891,655 USD (2025) while operating_income remained negative: operating_income = -564,973 USD (2024) and -551,918.
Open source ↗The SPAC has only minimal unrestricted cash outside the trust, meaning sponsor or PIPE funding must cover operating expenses, transaction costs, and potential redemptions until a deal closes.StrengtheningMateriality: Medium
cash = 1,208 USD (2023) -> 483,572 USD (2024) -> 112,660 USD (2025): unrestricted cash is very small relative to assets. Low unrestricted cash creates short-term liquidity risk: if the sponsor doesn’t fund administrative costs or a PIPE, the SPAC’s ability to execute or sustain due diligence and transaction activity is constrained and may increase the likelihood of abandoned deals or adverse deal terms.
Watch: Sponsor provides a bridge loan or expense support, or files Form 8-K announcing sponsor capital contributions (backstop).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash = 1,208 USD (2023) -> 483,572 USD (2024) -> 112,660 USD (2025): unrestricted cash is very small relative to.
Open source ↗The negative stockholders’ equity reported reflects the SPAC capital structure (redeemable public shares, warrants, sponsor interest) and implies potential dilution and structural complexity that can materially reduce public shareholders’ upside post-transaction.StrengtheningMateriality: Medium
equity = -97,944 USD (2023) -> -13,932,083 USD (2024) -> -14,484,001 USD (2025): persistent negative equity across years. Negative equity is a warning the capital structure and sponsor promote can leave public holders with a small residual stake after a combination, so deal terms and redemption rates are critical to value retention.
Watch: Sponsor agrees to roll significant equity into the combined company or cancels/forgives promote, improving public holder economics.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
equity = -97,944 USD (2023) -> -13,932,083 USD (2024) -> -14,484,001 USD (2025): persistent negative equity across years.
Open source ↗Negative operating cash flow shows the SPAC is using (or burning) small amounts of cash for operating/admin activities; unless sponsor or PIPE funding covers these costs, operating cash burn could constrain deal activity.StrengtheningMateriality: Medium
operating_cash_flow = -10,970 USD (2023) -> -584,718 USD (2024) -> -372,225 USD (2025): recurring negative operating cash flow. Sustained cash burn without sponsor support makes finding and closing a deal harder and increases probability of unfavorable terms or liquidation.
Watch: Sponsor provides expense advances or the company discloses reimbursement agreements, reducing net cash burn.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow = -10,970 USD (2023) -> -584,718 USD (2024) -> -372,225 USD (2025): recurring negative operating cash flow.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The SPAC’s ~ $300M in assets constitutes the primary deal capital and is sufficient to underwrite a substantial business combination if the sponsor finds a suitable target. If the trust assets fund a meaningful merger, public shareholders can realize upside from a successful business combination; if the trust is eroded or insufficient, the SPAC must rely on dilutive sponsor/PIPE funding or liquidate.
Reported positive net income is primarily non-operating — driven by interest/mark-to-market on trust assets — and therefore does not signal an operating business or recurring operating profitability. Net income today does not imply an ongoing profitable company; holders must judge the future operating economics of any merger partner, not the current GAAP net income of the SPAC.
The SPAC has only minimal unrestricted cash outside the trust, meaning sponsor or PIPE funding must cover operating expenses, transaction costs, and potential redemptions until a deal closes. Low unrestricted cash creates short-term liquidity risk: if the sponsor doesn’t fund administrative costs or a PIPE, the SPAC’s ability to execute or sustain due diligence and transaction activity is constrained and may increase the likelihood of abandoned deals or adverse deal terms.
The negative stockholders’ equity reported reflects the SPAC capital structure (redeemable public shares, warrants, sponsor interest) and implies potential dilution and structural complexity that can materially reduce public shareholders’ upside post-transaction. Negative equity is a warning the capital structure and sponsor promote can leave public holders with a small residual stake after a combination, so deal terms and redemption rates are critical to value retention.
Negative operating cash flow shows the SPAC is using (or burning) small amounts of cash for operating/admin activities; unless sponsor or PIPE funding covers these costs, operating cash burn could constrain deal activity. Sustained cash burn without sponsor support makes finding and closing a deal harder and increases probability of unfavorable terms or liquidation.
All standing thesis claims
Original report summary
GP-Act III is a blank-check vehicle whose value will come only from completing a high-quality business combination that converts its ~ $300M of trust assets into an attractive public company with limited shareholder redemptions.
BULL CASE / BEAR CASE
Bull case and bear case for GP-Act III Acquisition
Where the evidence on GP-Act III Acquisition stands: Holding on the latest evidence (Nov 8, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.
Bull case: what the evidence supports
The SPAC’s ~ $300M in assets constitutes the primary deal capital and is sufficient to underwrite a substantial business combination if the sponsor finds a suitable target.
Reported positive net income is primarily non-operating — driven by interest/mark-to-market on trust assets — and therefore does not signal an operating business or recurring operating profitability.
The SPAC has only minimal unrestricted cash outside the trust, meaning sponsor or PIPE funding must cover operating expenses, transaction costs, and potential redemptions until a deal closes.
The negative stockholders’ equity reported reflects the SPAC capital structure (redeemable public shares, warrants, sponsor interest) and implies potential dilution and structural complexity that can materially reduce public shareholders’ upside post-transaction.
Negative operating cash flow shows the SPAC is using (or burning) small amounts of cash for operating/admin activities; unless sponsor or PIPE funding covers these costs, operating cash burn could constrain deal activity.
Bear case: what would count against it
Large shareholder redemptions on merger announcement that reduce the trust proceeds available for the target.
The company announces and closes a business combination with an operating company whose operating_income becomes positive and material (i.e., the merged entity reports meaningful operating profits).
Sponsor provides a bridge loan or expense support, or files Form 8-K announcing sponsor capital contributions (backstop).
Thesis-Break Engine
Thesis-break watch · GP-Act III Acquisition
No break has crossed GP-Act III Acquisition’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MIXEDEntered a material definitive agreement.
GP-Act III Acquisition filed an SEC 8-K on 2026-11-04: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MIXEDEntered a material definitive agreement.
GP-Act III Acquisition filed an SEC 8-K on 2026-05-14: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MIXEDEntered a material definitive agreement.
GP-Act III Acquisition filed an SEC 8-K on 2026-05-13: Entered a material definitive agreement. It is a dated development that tests the current thesis.
RISKS / FALSIFIERS
What could break the thesis
- Large shareholder redemptions on merger announcement that reduce the trust proceeds available for the target.
- The company announces and closes a business combination with an operating company whose operating_income becomes positive and material (i.e., the merged entity reports meaningful operating profits).
- Sponsor provides a bridge loan or expense support, or files Form 8-K announcing sponsor capital contributions (backstop).
- Sponsor agrees to roll significant equity into the combined company or cancels/forgives promote, improving public holder economics.
- Sponsor provides expense advances or the company discloses reimbursement agreements, reducing net cash burn.
GPAT news
Loading headlines…
FINANCIAL STATEMENTS
GPAT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
GPAT: quick answers
- What is GPAT's short interest?
- As of October 30, 2026, 5,014 GPAT shares were sold short, down 4.3% from the count before. At the stock's average daily volume that is 1.8 days to cover. FINRA publishes the count twice a month. GPAT short interest history
